Shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) have received a consensus rating of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $33.25.
NAMS has been the topic of several analyst reports. TD Cowen assumed coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, May 15th. They issued a “buy” rating on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, July 30th.
Check Out Our Latest Research Report on NewAmsterdam Pharma
Insider Buying and Selling at NewAmsterdam Pharma
Institutional Trading of NewAmsterdam Pharma
Hedge funds have recently modified their holdings of the stock. Wolverine Asset Management LLC boosted its stake in NewAmsterdam Pharma by 197.2% during the 4th quarter. Wolverine Asset Management LLC now owns 8,694 shares of the company’s stock valued at $97,000 after purchasing an additional 5,769 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in NewAmsterdam Pharma by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock worth $3,359,000 after buying an additional 51,726 shares in the last quarter. Opaleye Management Inc. purchased a new position in NewAmsterdam Pharma during the 4th quarter worth $2,964,000. Yarbrough Capital LLC bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter worth $567,000. Finally, Jennison Associates LLC purchased a new stake in shares of NewAmsterdam Pharma in the first quarter valued at about $22,015,000. Institutional investors own 89.89% of the company’s stock.
NewAmsterdam Pharma Price Performance
Shares of NAMS stock opened at $17.02 on Monday. The business’s 50-day moving average price is $19.01 and its 200-day moving average price is $20.42. NewAmsterdam Pharma has a 12 month low of $5.63 and a 12 month high of $26.35.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.08). The company had revenue of $1.40 million for the quarter, compared to analyst estimates of $2.95 million. Analysts predict that NewAmsterdam Pharma will post -2.24 earnings per share for the current year.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Read More
- Five stocks we like better than NewAmsterdam Pharma
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Best Stocks Under $10.00
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Election Stocks: How Elections Affect the Stock Market
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.